See other companies on Welcome to the Jungle
Dyno Therapeutics
AI-powered gene therapy
- 101-200 employees
- Healthcare
- B2B
- Artificial Intelligence
- Deep Tech
- Biology
- Machine Learning
- Watertown, MA
Jump to section
Company mission
To use machine learning and quantitative experimentation to invent new ways to design gene vectors.
9% employee growth in 12 months
Our take
Gene therapy has the potential to revolutionize healthcare, but the effectiveness of these treatments is currently limited by the naturally occurring vectors (methods of transport for DNA) that scientists have available. Dyno Therapeutics is pioneering an AI-powered approach to gene therapy, that combines machine learning with quantitative high-throughput in vivo experimentation to produce targeted vectors that enable the treatment of a wide range of diseases.
Dyno's CapsidMap platform is capable of creating new and optimized AAV vectors, which are the most common method of delivery for gene therapy for human diseases. It is currently building up a portfolio of these vectors and, in 2021, partnered with Astellas to develop ones specified to skeletal and cardiac muscle. The company has raised impressive funds that will enable it to build out its team and seek new partnerships, as well as expand its platform into as-yet-unserved tissues.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Parental leave
- Vision coverage Health Savings Account
- 401(k) plan
- Free on-site parking
- 20 vacation days
- 40 hours of time off for volunteer work
- Unlimited sick days
- Commuter benefits
- Life Insurance & Disability Coverage
- Health & dental insurance through BCBS
- Access to KGA Life Services, which includes counseling, financial & legal consultations, and referrals for a wide range of services
- 12 paid holidays
- New facility in Watertown, MA
- Free on-site lunch daily
Company values
- Respect: We recognize the unique contributions of each individual and assume the best intent.
- Openness: We share decisions, successes, and failures transparently and honestly to enable others to do their best work.
- Support: We are mindful of others’ needs and well-being.
- Boldness: We fearlessly tackle ambitious scientific and organizational challenges in creative ways.
- Rigor: We practice a thorough and intentional approach to work to generate clearly interpretable results.
- Dedication to teamwork: We succeed as diverse, committed, and accountable teams.
- Empowering individuals: We enable professional growth through support of autonomy, cross-functional understanding and thoughtful risk-taking.
- Collaboration: We actively promote interaction between teams to stimulate innovation and learning.
- Sustainable success: We strive for long-term excellence by balancing joyful and fulfilling work with time to unplug.
Funding (2 rounds)
May 2021
$100m
SERIES A
May 2020
$9m
SEED
Total funding: $109m
This company has top investors
Leadership
Eric Kelsic
(CEO)Former Staff Scientist at the Wyss Institute for Biologically Inspired Engineering. PhD in Systems Biology from Harvard.
Sam Sinai
(ML Research Lead)Previously a Graduate Research Assistant at the Wyss Institute for Biologically Inspired Engineering. PhD in Mathematical and Computational Biology from Harvard.
Tomas Björklund
(Scientific Advisor)Professor of Neuroscience at Lund University. Former COO of Genepod Therapeutics.
Adrian Veres
(Scientific Co-Founder)Postdoctoral Research Fellow at Harvard, with a PhD in Systems Biology.